[Pharma-clinics. Medication of the month. Montelukast (Singulair)]

Montelukast (Singulair, Merck Sharp & Dohme) is a leukotriene receptor antagonist (LTRA) recommended in asthma inadequately controlled by inhaled corticosteroids, or in exercise-induced asthma. The molecule combines bronchoprotective, bronchodilating and anti-inflammatory effects. The drug has to be taken by the oral route at the dosage of 10 mg/day in adults and 5 mg/day in children under 15 years. In asthmatics montelukast decreases diurnal and nocturnal symptoms, the use of short-acting bronchodilator and improves lung function. The beneficial effects of montelukast are observed whether inhaled corticosteroids are concomitantly used or not. The drug is generally well tolerated and does not require serum monitoring. Montelukast is a complementary to inhaled corticosteroids in controlling asthma.